An Alzheimer’s Win: How Lilly Designed Donanemab Trial To Succeed
Phase II Results May Support Accelerated Approval
Lilly took a different path to positive results in Alzheimer’s with a smaller, biomarker-driven study to test the hypothesis that rapid, robust clearance of amyloid could slow disease progression, CEO David Ricks explains at J.P. Morgan.
